Success Metrics

Clinical Success Rate
88.8%

Based on 103 completed trials

Completion Rate
89%(103/116)
Active Trials
6(4%)
Results Posted
54%(56 trials)
Terminated
13(9%)

Phase Distribution

Ph phase_2
33
24%
Ph not_applicable
12
9%
Ph early_phase_1
2
1%
Ph phase_3
40
29%
Ph phase_1
17
12%
Ph phase_4
33
24%

Phase Distribution

19

Early Stage

33

Mid Stage

73

Late Stage

Phase Distribution137 total trials
Early Phase 1First-in-human
2(1.5%)
Phase 1Safety & dosage
17(12.4%)
Phase 2Efficacy & side effects
33(24.1%)
Phase 3Large-scale testing
40(29.2%)
Phase 4Post-market surveillance
33(24.1%)
N/ANon-phased studies
12(8.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.8%

103 of 120 finished

Non-Completion Rate

14.2%

17 ended early

Currently Active

6

trials recruiting

Total Trials

138

all time

Status Distribution
Active(9)
Completed(103)
Terminated(17)
Other(9)

Detailed Status

Completed103
Terminated13
unknown9
Recruiting5
Withdrawn4
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
138
Active
6
Success Rate
88.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.5%)
Phase 117 (12.4%)
Phase 233 (24.1%)
Phase 340 (29.2%)
Phase 433 (24.1%)
N/A12 (8.8%)

Trials by Status

unknown97%
not_yet_recruiting32%
active_not_recruiting11%
completed10375%
recruiting54%
withdrawn43%
terminated139%

Recent Activity

Clinical Trials (138)

Showing 20 of 138 trialsScroll for more
NCT05014776Phase 2

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Completed
NCT03785210Phase 2

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Terminated
NCT03993353Phase 2

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Completed
NCT05937854Phase 2

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

Recruiting
NCT05844462Phase 3

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

Recruiting
NCT07312955Not Applicable

Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females

Completed
NCT07245680Phase 3

COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

Not Yet Recruiting
NCT05206955Phase 3

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Recruiting
NCT07172815Phase 2

PDE5 Inhibitor for Alzheimer's Disease

Not Yet Recruiting
NCT06968962Not Applicable

Comparison of Sequential to Initial Combination Therapy in PAH

Recruiting
NCT06290713Phase 2

Vasodilator and Exercise Study for DMD (VASO-REx)

Recruiting
NCT03238365Early Phase 1

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

Completed
NCT04235270Phase 1

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Completed
NCT02558231Phase 3

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Completed
NCT05195775Phase 2

Tadalafil as Adjuvant Therapy for DMD

Active Not Recruiting
NCT04483115Phase 2

Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension

Completed
NCT05142254Phase 2

A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study

Completed
NCT06466369Phase 3

Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia

Completed
NCT06213077Not Applicable

The Effects of a Nitrate Supplementation on Erectile Function

Unknown
NCT04947631Phase 3

Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
138